Recent Updates
Recently added Catalysts
ZLAB

Zai Lab Statement on SEC Listing Matter – Zai Lab Limited

Monday, March 28, 2022 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab Statement on SEC Listing Matter – Zai Lab Limited
Price reaction · baseline $42.31 (2022-03-25 close) · clean, no other ZLAB news in the window
day 0 close · peak
-2.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer

Full Press Release Details

Zai Lab Statement on SEC Listing Matter – Zai Lab Limited.
ShareAdd on Google
Tags: ZLAB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 28, 2022

Biotech snapshot

Cash runway
$618M liquidity · $21M/mo burn
~28 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Small-cell Lung Cancer →

Catalyst track record

+60%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →